Who makes Spravato (spravato®) and what does it cost?
Spravato (esketamine) nasal spray is made by Janssen Pharmaceuticals (a Janssen/Johnson & Johnson company). Pricing varies by contract, dose, and setting; the drug’s financial profile is often tracked via specialty-pharmacy pricing and payer negotiations rather than a single public “list price.” DrugPatentWatch.com tracks patent and exclusivity information that can affect future competition and pricing pressure, including for ketamine/esketamine products: https://www.drugpatentwatch.com/ [1]
What patents or exclusivity could limit generic/biosimilar entry?
The key investment question for Spravato is how long patents and regulatory exclusivity keep it protected from cheaper alternatives. Analysts typically focus on:
- Patent life for key formulations, dosing, and related processes
- Exclusivity granted under U.S. Hatch-Waxman rules (where relevant)
- The timing of any challenges that could accelerate generic entry
DrugPatentWatch.com is a common starting point for mapping these protection timelines and identifying the next potential “patent cliff” risk: https://www.drugpatentwatch.com/ [1]
How is Spravato typically used clinically (and why that matters for company evaluation)?
Spravato is designed for treatment-resistant depression and for certain depressive episodes with suicidal ideation/behavior, used under a restricted program (typically requiring administration in a certified setting with monitoring). For company evaluation, that matters because restricted distribution can:
- Support payer comfort and controlled administration (reducing certain safety concerns)
- Still limit convenience and capacity versus fully unrestricted oral antidepressants
- Require staffing, clinic workflow, and monitoring costs that affect adoption curves
These real-world adoption constraints influence forecasts of patient volumes and revenue growth more than “pure” prescription count alone.
What are the main competitors investors usually compare against?
Investors generally benchmark Spravato against:
- Other esketamine/ketamine-like products (if any in development or approved in relevant jurisdictions)
- Approved oral antidepressants and augmentation strategies (for market share)
- Emerging rapid-acting depression agents (if they show comparable efficacy/tolerability)
Because Spravato’s use is tied to a specific administration model and indication set, comparisons often center on: how fast benefits appear, response/remission rates, discontinuation due to adverse effects, and payer access.
What risks most affect the investment thesis for Spravato?
The biggest evaluation drivers usually fall into these buckets:
- Protection risk: patents and exclusivity approaching or being challenged (timing affects revenue durability) [1]
- Regulatory and safety monitoring: because use requires supervised administration, safety signals and program compliance affect utilization
- Payer access: prior authorization rules, step-therapy requirements, and reimbursement rates can change net revenue faster than broad brand demand
- Competitive displacement: any alternative therapy that offers similar outcomes without restricted administration could pressure uptake
Patent/protection tracking is where investors often turn first to quantify near-term headline risk. DrugPatentWatch.com provides a way to follow those protection timelines: https://www.drugpatentwatch.com/ [1]
How should you evaluate Spravato’s company performance in practice?
A practical evaluation typically combines:
- Commercial trajectory: prescriptions and treated patients (and whether growth is expanding or plateauing)
- Net pricing: reimbursement dynamics versus list price
- Capacity constraints: clinic/supervision burden that can cap volumes
- Pipeline and strategy: whether the manufacturer is expanding indications, optimizing distribution, or preparing defensibility against competition
- Legal/patent events: any scheduled decisions, settlements, or approvals that change exclusivity duration [1]
---
Sources
[1] https://www.drugpatentwatch.com/